Therapy of treatment resistant depression: Focus on the management of TRD with atypical antipsychotics

CNS Spectrums

Volumn 9, Issue 11, 2004, Pages 823-832

  Klein, Nikolas ^a   Sacher, Julia ^a   Wallner, Helene ^a   Tauscher, Johannes ^a   Kasper, Siegfried ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMISULPRIDE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; DESIPRAMINE; FLUOXETINE; MAPROTILINE; MIANSERIN; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; ZIPRASIDONE; ZOTEPINE;

DEPRESSION; DRUG EFFICACY; ELECTROCONVULSIVE THERAPY; EXPERIENCE; HUMAN; MONOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOTHERAPY; RELAPSE; REVIEW; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT RESISTANT DEPRESSION; VAGUS NERVE STIMULATION;

EID: 10044234243     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900002248     Document Type: Review

References (91)

1. Fava M, Davidson KG, Frank E, Thase ME. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am. 1996;19:179-200.
2. Frank E, Thase ME. Natural history and preventative treatment of recurrent mood disorders. Annu Rev Med. 1999;50:453-468.
3. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington DC: American Psychiatric Press; 1994.
4. Paykel ES. Epidemiology of Refractory Depression. Chichester, UK: Wiley & Sons Ltd.; 1994.
5. Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry. 2001;62(suppl 16):10-17.
6. Souery D, Amsterdam J, de Montigny C, et al. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol. 1999;9:83-91
7. Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry. 1997;58(suppl 13):23-29.
8. Van Londen L, Molenaar RP, Goekoop JG, Zwinderman AH, Rooijmans HG. Three- to 5-year prospective follow-up of outcome in major depression. Psychol Med. 1998;28:731-735.
9. Paykel ES. Achieving gains beyond response. Acta Psychiatr Scand Suppl. 2002:12-17.
10. Bakish D. New standard of depression treatment: remission and full recovery. J Clin Psychiatry. 2001;62(suppl 26):5-9.
11. Quitkin FM, Rabkin JG, Stewart JW, McGrath PJ, Harrison W. Study duration in antidepressant research: advantages of a 12-week trial. J Psychiatr Res. 1986;20:211-216.
12. Poirier MF, Boyer P. Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison. Br J Psychiatry. 1999;175:12-16.
13. Thase MK, Kremer C, Rodrigues H. Mirtazapine versus sertraline after SSRI nonresponse. Poster presented at: annual Meeting of the American Psychiatric Association. May 5-10, 2001. New Orleans, LA, 2001.
14. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry. 2003;53:649-659.
15. Kennedy SH, Lam RW, Cohen NL, Ravindran AV. Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can J Psychiatry. 2001;46(suppl 1):38S-58S.
16. Stimpson N, Agrawal N, Lewis G. Randomised controlled trials investigating pharmacological and psychological interventions for treatment-refractory depression. Systematic review. Br J Psychiatry. 2002;181:284-294.
17. Posternak MA, Zimmerman M. Switching versus augmentation: a prospective, naturalistic comparison in depressed, treatment-resistant patients. J Clin Psychiatry. 2001;62:135-142.
18. Fava M, Papakostas GI, Petersen T, et al. Switching to bupropion in fluoxetine-resistant major depressive disorder. Ann Clin Psychiatry. 2003;15:17-22.
19. Nelson JC. Managing treatment-resistant major depression. J Clin Psychiatry. 2003;64(suppl 1)5-12.
20. Hirschfeld RM, Montgomery SA, Aguglia E, et al. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry. 2002;63:826-837.
21. Sethna ER, Schmauss M, Kapfhammer HP, Meyr P, Hoff P. A study of refractory cases of depressive illnesses and their response to combined antidepressant treatment. Br J Psychiatry. 1974;124:265-272.
22. Schmauss M, Kapfhammer HP, Meyr P, Hoff P. Combined MAO-inhibitor and tri- (tetra) cyclic antidepressant treatment in therapy resistant depression. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12:523-532.
23. Davidson J, McLeod M, Law-Yone B, Linnoila M. A comparison of electroconvulsive therapy and combined phenelzine-amitriptyline in refractory depression. Arch Gen Psychiatry. 1978;35:639-642.
24. Fava M, Zajecka JM, Jeffries H, Fawcett J. New approaches to the treatment of refractory depression. J Clin Psychiatry. 2000;61(suppl 1):26-32.
25. Zajecka JM, Jeffries H, Fawcett J. The efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment-resistant depression: a retrospective analysis. J Clin Psychiatry. 1995;56:338-343.
26. Weilburg JB, Rosenbaum JF, Biederman J, Sachs GS, Pollack MH, Kelly K. Fluoxetine added to non-MAOl antidepressants converts nonresponders to responders: a preliminary report. J Clin Psychiatry. 1989;50:447-449.
27. Nelson JC, Mazure CM, Bowers MB Jr, Jatlow PI. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry. 1991;48:303-307.
28. Fava M, Alpert J, Nierenberg A, et al. Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. J Clin Psychopharmacol. 2002;22:579-387.
29. Fava M, Rosenbaum JF, McGrath PJ, Stewart JW, Amsterdam JD, Quitkin FM. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry. 1994;151:1372-1374.
30. Amsterdam JD, Garcia-Espana F, Rosenzweig M. Clomipramine augmentation in treatment-resistant depression. Depress Anxiety. 1997;5:84-90.
31. Seth R, Jennings AL, Bindman J, Phillips J, Bergmann K. Combination treatment with noradrenalin and serotonin reuptake inhibitors in resistant depression. Br J Psychiatry. 1992;161:562-565.
32. Bondolfi G, Chautems C, Rochat B, Bertschy G, Baumann P. Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation. Psychopharmacology (Berl). 1996;128:421-425.
33. Hunchak J. SSRI combination treatment for depression. Can J Psychiatry. 1997;42:531-532.
34. Ferreri M, Lavergne F, Berlin I, Payan C, Puech AJ. Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone. Acta Psychiatr Scand. 2001;103:66-72.
35. Maes M, Libbrecht I, van Hunsel F, Campens D, Meltzer HY. Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. J Clin Psychopharmacol. 1999;19:177-182.
36. DeBattista C, Solvason HB, Poirier J, Kendrick E, Schatzberg AF. A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants. J Clin Psychophamacol. 2003;23:27-30.
37. Lam RW, Hossie H, Solomons K, Yatham LN. Citalopram and bupropion-SR: combining versus switching in patients with treatment-resistant depression. J Clin Psychiatry. 2004;65:337-340.
38. Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry. 2002;51:183-188.
39. Carpenter LL, Jocic Z, Hall JM, Rasmussen SA, Price LH. Mirtazapine augmentation in the treatment of refractory depression. J Clin Psychiatry. 1999;60:45-49.
40. Bauer M, Adli M, Baethge C, et al. Lithium augmentation therapy in refractory depression: clinical evidence and neurobiological mechanisms. Can J Psychiatry. 2003;48:440-448.
41. Bauer M, Forsthoff A, Baethge C, et al. Lithium augmentation therapy in refractory depression-update 2002. Eur Arch Psychiatry Clin Neurosci. 2003;253:132-139.
42. Bschor T, Berghofer A, Strohle A, et al. How long should the lithium augmentation strategy be maintained? A 1-year follow-up of a placebo-controlled study in unipolar refractory major depression. J Clin Psychopharmacol. 2002;22:427-430.
43. Kennedy SH, Segal ZV, Cohen NL, Levitan RD, Gemar M, Bagby RM. Lithium carbonate versus cognitive therapy as sequential combination treatment strategies in partial responders to antidepressant medication: an exploratory trial. J Clin Psychiatry. 2003;64:439-444.
44. Katona CL, Abou-Saleh MT, Harrison DA, et al. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatry. 1995;166:80-86.
45. Baumann P, Nil R, Souche A, et al. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and phannacogenetic investigation. J Clin Psychopharmacol. 1996;16:307-314.
46. Nierenberg AA, Papakostas GI, Petersen T, et al. Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants. J Clin Psychopharmacol. 2003;23:92-95.
47. Aronson R, Offman HJ, Joffe RT, Naylor CD: Triiodothyronine augmentation in the treatment of refractory depression: a meta-analysis. Arch Gen Psychiatry. 1996;53:842-848.
48. Landen M, Bjorling G, Agren H, Fahlen T. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSR1 in patients with treatment-refractory depression. J Clin Psychiatry. 1998;59:664-668.
49. Appelberg BG, Syvalahti EK, Koskinen TE, et al. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J Clin Psychiatry. 2001;62:448-452.
50. Fischer P, Tauscher J, Kufferle B, Kasper S. Weak antidepressant response after buspirone augmentation of serotonin reuptake inhibitors in refractory severe depression. Int Clin Psychopharmacol. 1998;13:83-86.
51. Fava M. Augmentation and combination strategies in treatment-resistant depression. J Clin Psychiatry. 2001;62(suppl 18):4-11.
52. Fawcett J, Kravitz HM, Zajecka JM, Schaff MR. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. J Clin Psychopharmacol. 1991;11:127-132.
53. Perez V, Gilaberte I, Fanes D, Alvarez E, Artigas F. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet. 1997;349:1594-1597.
54. Bordet R, Thomas P, Dupuis B: Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo-controlled trial. Reseau de Recherche et d'Experimentation Psychopharmacologique. Am J Psychiatry. 1998;155:1346-1351.
55. Perez V, Soler J, Puigdemont D, Alvarez E, Artigas F. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius. Arch Gen Psychiatry. 1999;56:375-379.
56. Moreno FA, Gelenberg AJ, Bachar K, Delgado PL. Pindolol augmentation of treatment-resistant depressed patients. J Clin Psychiatry. 1997;58:437-439.
57. Su KP, Huang SY, Chiu CC, Shen WW. Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol 2003;13:267-271.
58. Murck H, Song C, Horrobin DF, et al. Ethyl-eicosapentaenoate and dexamethasone resistance in therapy-refractory depression. Int J Neuropsychopharmacol. 2004;7:341-349.
59. Pope HG Jr, Cohane GH, Kanayama G, Siegel AJ, Hudson JI. Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial. Am J Psychiatry. 2003;160:105-111.
60. Höflich GK, Kasper S, Rao ML, et al. Ansprechen auf Elektrokrampftherapie und hormonelle Parameter bei Patienten mit therapieresistenter Depression. [Efficacy of electroconvulsive terapy and hormonal parameters in patients with TRD] In: Peters UH, Schifferdecker M, Krahl A, eds. 150 Jahre Psychiatric Jubiläumswerk der Deutsche Gesellschaft für Psychiatrie und Neurologie (DGPN). Cologne, Germany: Martini Verlag; 1996:469-471. [in German].
61. Birkenhager TK, Pluijms EM, Lucius SA. ECT response in delusional versus non-delusional depressed inpatients. J Affect Disord. 2003;74:191-195.
62. Hasse-Sander I, Muller H, Schurig W, Kasper S, Moller HJ. Effects of electroconvulsive therapy on cognitive functions in therapy-refractory depression [German]. Nervenarzt. 1998;69:609-616.
63. Tauscher J, Neumeister A, Fischer P, Frey R, Kasper S. Electroconvulsive therapy in clinical practice [German]. Nervenarzt. 1997;68:410-416.
64. Quiner S, Letmaier M, Barnas C, Heiden A, Kasper S. Transcranial magnetic stimulation (TMS) - from diagnostic procedure to therapy [German]. Wien Klin Wochenschr. 2002;114:181-186.
65. Fitzgerald PB, Brown TL, Marston NA, Daskalakis ZJ, De Castella A, Kulkarni J. Transcranial magnetic stimulation in the treatment of depression: a double-blind, placebo-controlled trial. Arch Gen Psychiatry. 2003;60:1002-1008.
66. Rush AJ, George MS, Sackeim HA, et al. Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study. Biol Psychiatry. 2000;47:276-286.
67. Sackeim HA, Rush AJ, George MS, et al. Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome. Neuropsychopharmacology. 2001;25:713-728.
68. Marangell LB, Rush AJ, George MS, et al. Vagus nerve stimulation (VNS) for major depressive episodes: one year outcomes. Biol Psychiatry. 2002;51:280-287.
69. Segal ZV, Whitney DK, Lam RW: Clinical guidelines for the treatment of depressive disorders. III. Psychotherapy. Can J Psychiatry. 2001;46(suppl 1):29S-37S.
70. Robertson MM, Trimble MR. Major tranquillisers used as antidepressants. A review. J Affect Disord. 1982;4:173-193.
71. Schatzberg AF, Rothschild AJ. Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV? Am J Psychiatry. 1992;149:733-745.
72. Nelson JC. The Use of Antipsychotic Drugs in the Treatment of Depression. New York, NY: PMA Publishing Corp.; 1987.
73. Kasper S: How much do novel antipsychotics benefit the patients? Int Clin Psychopharmacol. 1998;13(suppl 3):S71-S77.
74. Kasper S, Resinger E. Cognitive effects and antipsychotic treatment. Psychoneu roendocrinology. 2003;28(suppl 1):27-38.
75. Kasper S, Stamenkovic M, Letmaier M, Schreinzer D. Atypical antipsychotics in mood disorders. Int Clin Psychopharmacol. 2002;17(suppl 3):S1-S10.
76. Boyer PL, Boyer P, Lecrubier Y, Stalla-Bourdillon A, Fleurot O. Amisulpride versus amineptine and placebo for the treatment of dysthymia. Neuropsychobiology. 1999;39:25-32.
77. Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry. 2001;158:131-134.
78. Corya SA, Andersen SW, Detke HC, et al. Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study. J Clin Psychiatry. 2003;64:1349-1356.
79. Emsley RA, Buckley P, Jones AM, Greenwood MR. Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia. J Psychopharmacol. 2003;17:210-215.
80. Sajatovic M, Mullen JA, Sweitzer DE. Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis. J Clin Psychiatry. 2002;63:1156-1163.
81. Khouzam HR. Treatment of depressive mood in schizophrenia with the atypical antipsychotic quetiapine. Depress Anxiety. 2000;11:80-82.
82. Kasper S, Heiden A Augmentation of citalopram with quetiapine. European Neuropsychopharmacology. In press.
83. Knopf U, Hubrich-Ungureanu P, Thome J. Paroxetine augmentation with risperidone in therapy-resistant depression [German]. Psychiatr Prax. 2001;28:405-406.
84. Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry. 1999;60:256-259.
85. O'Connor M, Silver H. Adding risperidone to selective serotonin reuptake inhibitor improves chronic depression. J Clin Psychopharmacol. 1998;18:89-91.
86. Rapaport MC, Canuso C, Loecher A, Lasser R, Gharabawi G. Preliminary results from the ARISe-RD trial. Poster presented at: annual meeting of the American Psychiatric Association. May 17-22, 2003. San Francisco, Calif.
87. Stoll AL, Haura G. Tranylcypromine plus risperidone for treatment-refractory major depression. J Clin Psychopharmacol. 2000;20:495-496.
88. Dunner DA, Amsterdam JD, Shelton RC, Hassman H, Rosenthal M, Romano S. Adjunctive ziprasidone in treatment resistant depression: a pilot study. Poster presented at: annual meeting of the American Psychiatric Association. May 17-22, 2003. San Francisco, Calif.
89. Papakostas GI, Peterson T, Worthington J. Ziprasidone augmentation for major depressive disorder rfractory to SSR1s. Poster presented at: annual meeting of the American Psychiatric Association. May 17-22, 2003. San Francisco, Calif.
90. Wolfersdorf M, Konig F, Straub R. Pharmacotherapy of delusional depression: experience with combinations of antidepressants with the neuroleptics zotepine and haloperidol. Neuropsychobiology. 1994;29:189-193.
91. Wolfersdorf M, Barg T, Konig F, Leibfarth M, Grunewald I. Paroxetine as antidepressant in combined antidepressant-neuroleptic therapy in delusional depression: observation of clinical use. Pharmacopsychiatry. 1995;28:56-60.